Bergen, Norway, June 4th, 2024: Today, Lifecare ASA (LIFE), a clinical stage
medical sensor company developing the next generation Continuous Glucose
Monitor (CGM), announces that the company has filed an application for a new
patent to the European Patent Office (EPO).
Reference is made to previous communication of the potential of the sensor
technology beyond glucose measurements, which the company focuses on today.
For use in Lifecare's already patented and proprietary technology utilizing
osmotic pressure as glucose sensor principle, the Company has developed a new
conceptual chemistry composition including modular receptor molecules for
detection of a wide range of diseases or conditions.
The chemistry invention comprises different receptors (cellular, biological,
artificial and synthesized, oligonucleotides, inorganic receptor layers or the
like) to induce changes in the osmotic pressure. The purpose of the invention
is to identify and/or monitor diseases or conditions of acute or chronic
disorders, such as cardiovascular disease, metabolic disorders, infections,
immune diseases or the like, in addition to Lifecare's primary focus on
diabetes.
The patent-filing indicates that Lifecare is developing towards a broader
reach as a sensor company, beyond monitoring of glucose. While the Company's
focused mission is to provide better solutions for people with diabetes, the
patent-filing is very much aligned with Lifecare's main goal to improve lives
through medical technology. The patent-filing is a confirmation of the
ambitions as a sensor company based on a platform technology applicable to
identify and/or monitor a broad range of diseases or conditions of acute or
chronic disorders.
The development is a result of innovative research and development at Lifecare
Chemistry Ltd. (Bristol, UK), a fully owned subsidiary of Lifecare ASA.
Lifecare Chemistry was established in 2022 as a development unit with the main
task to improve the chemistry compositions for glucose detection, in
particular the sensing sensitivity, and to accelerate Lifecare's intention to
develop a modular system for detection and/or monitoring of various analytes
beyond glucose. The subsidiary is led by Dr. Jordan Edward Gardiner, while
Professor Tony James at the University of Bath acts as an important expert
consultant in chemistry development.
-It is an important achievement for Lifecare to file this patent application.
We are strongly committed to bringing our Continuous Glucose Monitor to the
veterinary and human market. In addition, we believe that our sensor principle
and sensor hardware have great opportunities beyond glucose monitoring, and we
must ensure appropriate protection of this broad potential. The new innovation
is expected to both, further improvement of our glucose measurement
capacities, as well as being a door opener for measurements in other areas
with high commercial interest, says CEO Joacim Holter at Lifecare ASA.
Previously granted patent from EPO:
March 21st, 2024, Lifecare announced that EPO had granted a new patent to
Lifecare. The patent was related to chemistry compositions and method for
preparing the composition and use, specifically of Lifecare's original and
proprietary fluid composition reactive to glucose. This active fluid enables
monitoring of glucose in Lifecares miniaturized sensor-technology, by the
means of osmotic pressure as the sensing principle and is improving:
* sensor lifetime
* measurement response time
* measurement sensitivity
About us
Lifecare ASA is a clinical stage medical sensor company developing technology
for sensing and monitoring of various body analytes. Lifecare's main focus is
to bring the next generation of Continuous Glucose Monitoring ("CGM") systems
to market. Lifecare enables osmotic pressure as sensing principle, combined
with the ability to manipulate Nano-granular Tunnelling Resistive sensors
("NTR") on the sensor body for read-out of pressure variations. Lifecare's
sensor technology is referred to as "Sencell" and is suitable for identifying
and monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.
Contacts
For further information, please contact:
Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40
Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42